Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 15/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17634687 | 0.93 | PRKDC (0.51) | PRKDCFAAHSLC40A1ALDH1A1CYP1A2 | |
| SCHEMBL17635390 | 0.93 | PRKDC (0.49) | PRKDCFAAHSLC40A1ALDH1A1CYP1A2 | |
| SCHEMBL17634700 | 0.92 | PRKDC (0.49) | PRKDCFAAHSLC40A1 | |
| SCHEMBL17634795 | 0.91 | PRKDC (0.54) | PRKDCFAAHSLC40A1PDK1ALDH1A1 | |
| SCHEMBL17634688 | 0.91 | PRKDC (0.48) | PRKDCFAAHSLC40A1ALDH1A1CYP1A2 | |
| SCHEMBL17634628 | 0.91 | PRKDC (0.48) | PRKDCFAAHSLC40A1ALDH1A1CYP1A2 | |
| SCHEMBL17634699 | 0.91 | FAAH (0.49) | PRKDCFAAHSLC40A1CYP1A2CLK4 | |
| SCHEMBL17634762 | 0.91 | PRKDC (0.48) | PRKDCFAAHSLC40A1ALDH1A1CYP1A2 | |
| SCHEMBL17634771 | 0.90 | PRKDC (0.55) | PRKDCFAAHSLC40A1ALDH1A1CYP1A2 | |
| SCHEMBL19355282 | 0.90 | PRKDC (0.53) | PRKDCFAAHSLC40A1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| US-10442791-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-10-15 | — | — | US | disclosed |
| US-10391095-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-27 | — | — | US | disclosed |
| US-9925188-B2 | DNA-PK inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925188-B2 | DNA-PK inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-27 | — | — | US | disclosed |
| US-9878993-B2 | DNA-PK inhibitors for treatment of cancer | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878993-B2 | DNA-PK inhibitors for treatment of cancer | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-30 | — | — | US | disclosed |
| US-9592232-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-14 | — | — | US | disclosed |
| US-9592232-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-14 | — | — | US | disclosed |
| US-9376448-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376448-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-28 | — | — | US | disclosed |
| US-9296701-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296701-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008305-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885FAAH 3955/4885SLC40A1 4477/4885 |
| US-10442791-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885FAAH 3955/4885SLC40A1 4477/4885 |
| US-10391095-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885FAAH 3955/4885SLC40A1 4477/4885 |
| US-11021465-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885FAAH 3955/4885SLC40A1 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.